GENEVA, Sept. 18 -- PRECISEMAB BIOTECH CO., LTD. filed a patent application (CN2026/081771) for “CONDITIONALLY ACTIVATED LOCK-ANTI-EGFR ANTIBODY FOR CANCER THERAPY”. With publication no. WO/2026/184705, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 47/65
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....